Advanced Search

 

Study ID Status Title Patient Level Data
SAM40032 Completed A multi-centre, open label study to demonstrate the efficacy and tolerability of Seretide Accuhaler 50/100, 50/250 or 50/500mg twice daily after substituting for budesonide or beclomethasone dipropionate in doses of 500mg up to 2000mg daily in subjects with reversible airways obstruction.
SAM40034 Completed A double-blind, randomised, parallel group, 12-week comparison of fluticasone propionate/salmeterol combination Diskus 100/50mcg BID with fluticasone propionate (FP) 250mcg BID as initial maintenance treatment in persistent asthma (Seretide Nordic Jump-Up Study)
SAM40036 Completed A 12-week multicentre, randomised, double-blind, double-dummy, parallel group study to compare the efficacy and tolerability of once daily salmeterol/fluticasone propionate combination (salm/FP) 50/100mcg at night via the DISKUS/ACCUHALER with once daily budesonide (BUD) 400mcg at night via a breath-actuated dry powder inhaler (BADPI) as initial maintenance therapy in mild-to-moderate asthmatic subjects Study Listed on ClinicalStudyDataRequest.com
SAM40040 Completed A 24-week, randomsed, double dummy, double blind, parallel group study to compare the occurence of exacerbations between Seretide Diskus 50/250 bd and Symbicort BADPI (Turbuhaler) 4.5/160 two inhalations bd in subjects with moderate to severe asthma Study Listed on ClinicalStudyDataRequest.com
SAM40042 Completed A double-blind, double-dummy, randomised, cross-over study to compare the bronchodilating action of Seretide Accuhaler 50/100mcg and Symbicort breath-actuated dry powder inhaler 6/200mcg in subjects with asthma after a single dose before and after 4 weeks of treatment Study Listed on ClinicalStudyDataRequest.com
SAM40047 Completed Duration of action of single inhalations of the salmeterol/ fluticasone combination product (50/250 µg) in comparison with the formoterol/ budesonide combination product (4.5/160 µg) in patients with moderate asthma - a randomised, double-blind, double-dummy, cross over study.
SAM40048 Completed Randomised, double-blind, parallel group study on the efficacy and tolerability of the salmeterol 50 mcg / fluticasone 250 mcg combination Diskus compared to the formoterol 6 mcg / budesonide 200 mcg combination turbohaler administered twice daily in patients with moderate bronchial asthma.
SAM40049 Completed A Danish, multi-centre, comparative, parallel-group study to determine whether initiation of combination treatment with Seretide™ 50/100 mg bd offers better asthma control than monotherapy with Flixotide™ 100 mg bd to adult asthmatic subjects uncontrolled on short-acting bronchodilator alone.
SAM40056 Completed Randomised, double-blind, double-dummy, 52-week, parallel group study of a standard dosing regimen with salmeterol/fluticasone propionate50/250 twice daily Diskus versus a symptom-driven, variable dosing regimen with formoterol/budesonide combination 4.5/160 in adult asthmatics Study Listed on ClinicalStudyDataRequest.com
SAM40058 Completed A double-blind, randomised, parallel group study to evaluate the safety and tolerability of administering two inhalations twice daily of the salmeterol/fluticasone propionate combination (SERETIDE) in subjects with asthma over two weeks. Study Listed on ClinicalStudyDataRequest.com
SAM40062 Completed A single-centre, single-dose, double-blind, double-dummy, placebo-controlled, randomised, three-way crossoverstudy to compare the duration of action of SERETIDE* DISKUS* 50/100mcg versus formoterol/budesonidecombination 4.5/160mcg Breath-Actuated Dry Powder Inhaler (BADPI) in subjects with asthma Study Listed on ClinicalStudyDataRequest.com
SAM40065 Completed A multicenter, randomized, double-blind, parallel group, 40-week comparison of asthma control using bronchial hyperresponsiveness as an additional guide to long-term treatment in adolescents and adults receiving either fluticasone propionate/sameterol DISKUS twice daily or fluticasone propionate DISKUS twice daily (or placebo twice daily if asymptomatic) Study Listed on ClinicalStudyDataRequest.com
SAM40066 Completed A Muticenter, Randomized, Double-Blind, Double-Dummy, Placebo Controlled, Parallel Group, Four-Week Study Assessing the Efficacy of Fluticasone Propionate Aqueous Nasal Spray 200mcg every day versus Montelukast 10mg every day in Adolescent and Adult subjects with Asthma and Seasonal allergic rhinitis who are Receiving Concurrent Open-Label Advair Diskus 100/50mcg twice daily Study Listed on ClinicalStudyDataRequest.com
SAM40067 Completed A multicentre, randomized, open-label, parallel-group, six-week treatment study to evaluate the efficacy and safety of Seretide (Salmeterol/Fluticasone propionate combination product) 50/100 mg strength bd via Accuhaler™ inhaler vs Pulmicort Turbuhaler™ 400 mg bd in Chinese adults with asthma
SAM40086 Completed A multicenter, randomized, double-blind, parallel group, 40-week comparison of asthma control using bronchial hyperresponsiveness as an additional guide to long-term treatment in adolescents and adults receiving either fluticasone propionate/salmeterol DISKUS twice daily or fluticasone propionate DISKUS twice daily (or placebo BID if asymptomatic) Study Listed on ClinicalStudyDataRequest.com
SAM40088 Completed Maintenance of asthma control in adults: comparison of three therapeutic strategies in patients whose asthma is controlled by a medium dose of inhaled corticosteroid and a long-acting inhaled beta2-agonist
SAM40090 Completed A Twelve Week Multi-Centre, Randomized, Double-Blind, Parallel Group, Comparative Trial of Advair 50/100 mcg Diskus Inhalation Device BID versus Flovent 250 mcg Diskus Inhalation Device BID in Adolescents and Adults with Persistent Asthma (Program of Advair Control and Effectiveness – Advair Low ...
SAM40092 Completed Effect of salmeterol/fluticasone propionate combination product on seasonal changes in airway responsiveness and exhaled nitric oxide in subjects with pollen-induced asthma.
SAM40100 Completed Randomised, double-blind parallel group study to assess the bronchodilative and bronchoprotective properties of SERETIDE DISKUS ® inhlaer 50/100mcg twice daily vs. FLIXOTIDE® inhaler 200mcg twice daily. Study Listed on ClinicalStudyDataRequest.com
SAM40101 Completed A pilot single centre, randomised, double-blind, crossover study to demonstrate the superiority of Salmeterol/fluticasone propionate combination product 50/100mcg bd versus fluticasone propionate 100mcg bd when treated for two weeks with respect to activity levels in children aged 7-15 years. Study Listed on ClinicalStudyDataRequest.com
SAM40104 Completed Randomised, double blind, parallel group study to assess the bronchodilative and bronchoprotective properties of SERETIDE DISKUS® inhaler 50/100 mcg twice daily vs FLIXOTIDE® inhaler 200 mcg twice daily Study Listed on ClinicalStudyDataRequest.com
SAM40114 Completed A post-marketing surveillance study on the real world use of SFC (Salmeterol /Fluticasone Propionate Combination) in Ireland
SAM40116 Completed A 12-week multi-centre, randomised, double blind, parallel group study to compare the efficacy of salmeterol/fluticasone propionate (Seretide TM) 50/100 mcg or 50/250 mcg twice daily and fluticasone propionate (Flixotide TM) 250 mcg or 500 mcg twice daily via the Diskus TM in subjects with asthm ...
SAM40120 Completed A phase IV, multi-centre, double-blind, parallel group, randomised study comparing Seretide (50/100mcg bd) via the Evohaler (MDI-HFA) with Flixotide (250mcg bd) via the Evohaler (MDI-HFA) in asthmatics with significant smoking history
SAM40121 Completed Summary of the efficacy and safety and safety of salmeterol 50mcg and fluticasone propionate 100mcg administered in Diskus Dry Powder Inhaler twice daily in steroid experienced children with reversible airways obstruction

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.